Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?
{{output}}
The Congressional Budget Office (CBO) created a model of new drug development with the aim of informing the US Congress about the potential impact of policy changes affecting expected biopharmaceutical revenue on future innovation. While models are by their na... ...
